 At the European Hematology Association EHA meeting, Oncternal Therapeutics Inc NASDAQ: ONCT presented initial preclinical results of Oncternals ROR1 CAR containing the antigen-binding region of zilovertamab. The data showed that The ROR1 CAR mediated target. 